newsfilter
← Latest News
Business Wire·

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into